Navigation Links
Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
Date:9/13/2010

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice President of Finance, will provide a company overview at 11:30am, EDT, Friday, September 17, 2010 at the Four Seasons Hotel in Boston, Massachusetts.

(Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100913/NE63515LOGO)

About MerrimackMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack has three oncology candidates in clinical development: MM-121, partnered with sanofi-aventis, in Phase 2 clinical testing, MM-111 in Phase 1/2 clinical testing, MM-398, partnered with PharmaEngine, Inc., in Phase 2 clinical testing and multiple pre-clinical development and research stage programs in the pipeline. MM-121, MM-111, and MM-398 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com. ContactsKathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli@merrimackpharma.com, http://www.merrimackpharma.com Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy@raymondstevenson.com
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
2. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and Markets has announced the addition of the "Vital Signs Monitoring ... Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size was worth $3,694 ... growing at a CAGR of 5.8% from 2016 to 2022. ... in global vital signs monitoring devices industry. The blood pressure monitoring devices ...
(Date:1/18/2017)... 2017   Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies to ... reported the Company,s operating results for 2016 and an ... the Company described in its recent 10-K filing with ... accomplishments. The Company,s contract laboratory completed its evaluation of ...
(Date:1/18/2017)... 18, 2017 Research and Markets has announced ... Market 2017-2021" report to their offering. ... The global CINV drugs market to ... Global Thoracic Surgery Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 2017 , ... Floundering on New Year’s resolutions? Need an excuse to get ... reset. The U.S. Apple Association agrees and recommends starting each day with apples, ... to heart disease. , The U.S. Apple Association – which represents apple growers and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... difference. Eden Activewear is a stand-out company for several differences from other mainstream ... only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . ...
(Date:1/17/2017)... Fla (PRWEB) , ... January 17, 2017 , ... SunView ... Excellence Award for Innovation of the Year. , Each year, Pink Elephant ... taken an innovative approach to address a specific business problem or opportunity. The award ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... as Palm Desert, is opening a new office in San Clemente, California this ... stimulation (dTMS) in Southern California, successfully treating individuals struggling with major depression. Depression ...
(Date:1/17/2017)... York (PRWEB) , ... January 17, 2017 , ... ... – SightMD – will lecture to primary eye care practitioners on the latest ... at the upcoming 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey ...
Breaking Medicine News(10 mins):